New oral anticoagulants and atrial fibrillation: Differentiating between "no proof of difference" and "proof of no difference" for new oral anticoagulants

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Messori, Andrea ^a   Fadda, Valeria ^a   Gatto, Roberta ^a   Maratea, Dario ^a   Trippoli, Sabrina ^a  

^a HTA Unit Area Vasta Centro Toscana Regional Health System   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG RESEARCH; EMBOLISM; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; NOTE; PRIORITY JOURNAL; THERAPEUTIC EQUIVALENCE; LETTER; META ANALYSIS (TOPIC); METHODOLOGY; STANDARD; TREATMENT OUTCOME;

ANTICOAGULANTS; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; TREATMENT OUTCOME;

EID: 84902833137     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g1955     Document Type: Note

References (9)

1. Torjesen I. New anticoagulants should be considered for atrial fibrillation, says NICE. BMJ 2014;348:g313. (21 January.)
2. Messori A. Overlapping meta-analyses on novel oral anticoagulants in atrial fibrillation [comment]. Pub Med Commons 2014. www.ncbi.nlm.nih.gov/ pubmed/22912382# cm22912382-3178.
3. Moher D. The problem of duplicate systematic reviews. BMJ 2013;347:f5040.
4. Goggins A. Duplicate systematic reviews. Repeated meta-analyses are both worthy and to be encouraged. BMJ 2013;347:f5508.
5. Società Italiana di Farmacologia, Italian Society of Pharmacology. Position paper: equivalenze di classe terapeutica nell'area degli anticoagulanti orali. 2013. www.sifweb.org/docs/sif-position-paper%20-anticoag- orali.pdf.
6. Società Italiana di Farmacia Clinica e Terapia, Italian Society of Clinical Pharmacy and Therapeutics. Position paper: equivalenza terapeutica dei nuovi anticoagulanti orali. 2014. www.sifact.it/joomla/index.php/documenti/67- position-paper-sifact.
7. Italian Agency of Medicines. "Decreto Balduzzi", Art. 15, comma 11-bis, Legge 7 agosto 2012 n. 135 (effective November 2012). www.agenziafarmaco.gov.it/it/content/aggiornamento-al-15052013-delle-tabelle- con-lista-farmaci-di-classe-consentire-tutti-gliope.
8. Messori A, Maratea D, Fadda V, Trippoli S. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban. Eur J Clin Pharmacol 2014; published online 23 Jan.
9. Messori A, Fadda V, Maratea D, Trippoli S. Rates of inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant Factor VIII: no proof of difference or proof of no difference? Semin Thromb Hemost 2014;40:269-70.